Compare LEXX & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEXX | BFRI |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | Canada | United States |
| Employees | 7 | 94 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 13.2M |
| IPO Year | N/A | N/A |
| Metric | LEXX | BFRI |
|---|---|---|
| Price | $0.88 | $1.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.50 | ★ $2.75 |
| AVG Volume (30 Days) | ★ 186.8K | 123.9K |
| Earning Date | 04-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | $601.47 | $16.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.54 |
| 52 Week High | $1.55 | $1.18 |
| Indicator | LEXX | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 64.18 |
| Support Level | $0.81 | $0.79 |
| Resistance Level | $1.05 | $1.17 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 10.12 | 68.49 |
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.